Ignacio Sanz is a Rheumatology/Immunology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4901 Lac De Ville Blvd
Bldg D Suite 240
Rochester, NY 146185647
Telephone
585-341-7900Registry record last updated 30 Oct 2007.
Clinical trials
- SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy
Sponsor: University Hospital Virgen de las Nieves
- Urethral Stricture After Transurethral Resection of the Prostate/Bladder: a Prospective Study of Risk Factors
Sponsor: University Hospital Virgen de las Nieves
- COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year20258 payments$10,987openpaymentsdata.cms.gov ↗
- Novartis Pharmaceuticals CorporationProgram year20254 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Antiparasitic
52.6%Antimalarial52.6%Hydroxychloroquine Sulfate100%Part D<11 patientsMetabolism & gastrointestinal
17.9%Corticosteroid17.9%Prednisone100%Part D<11 patientsCancer & immunology
15.8%Purine Antimetabolite15.8%Azathioprine100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
14 NIH research awards on record, funded 1996–2013 per NIH RePORTER. The latest:
- Translational Research Project Effector and Regulatory B cells in SLE
University of Rochester
FY2013$254,081U19AI056390 - Translational Research Project Effector and Regulatory B cells in SLE
University of Rochester
FY2012$284,124U19AI056390 - A Model System for the Study of Human B-cell Tolerance
University of Rochester
FY2012$120,152R37AI049660
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”